<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19378" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Oral Mucositis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bell</surname>
            <given-names>Andrea</given-names>
          </name>
          <aff>Michigan State University College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasi</surname>
            <given-names>Anup</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrea Bell declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anup Kasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19378.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Oral mucositis is a severely debilitating condition characterized by erythema, edema, and ulcerations of the oral mucosa. It is a complication of radiation therapy (RT) to the head and neck, chemotherapy, chemoradiotherapy, and hematopoeitic stem cell transplantation (HSCT). The lesions can also break the mucosa barrier resulting in local or systemic infection. In severe cases, this can lead to parenteral nutrition, ultimately leading to poor quality of life. This activity reviews the etiology, pathophysiology, history and physical, evaluation, and treatment of oral mucositis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of oral mucositis.</p></list-item><list-item><p>Summarize the pathophysiology of oral mucositis.</p></list-item><list-item><p>Identify the physical exam findings of oral mucositis and its evaluation.</p></list-item><list-item><p>Review the management options available to prevent and treat oral mucositis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19378&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19378">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19378.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Oral mucositis is a severely debilitating condition&#x000a0;characterized by&#x000a0;erythema,&#x000a0;edema, and ulcerations&#x000a0;of the oral mucosa.<xref ref-type="bibr" rid="article-19378.r1">[1]</xref> It is a complication of radiation therapy (RT) to the head and neck, chemotherapy, chemoradiotherapy, and hematopoeitic stem cell transplantation (HSCT).<xref ref-type="bibr" rid="article-19378.r2">[2]</xref>&#x000a0;Oral intake may be impaired due to pain,&#x000a0;which in some cases may lead to the need for parenteral nutrition.<xref ref-type="bibr" rid="article-19378.r3">[3]</xref> In addition, the oral lesions weaken the mucosa barrier resulting in local or systemic infection.<xref ref-type="bibr" rid="article-19378.r4">[4]</xref>&#x000a0;</p>
        <p>In severe oral mucositis caused by chemotherapy, the dose in the subsequent chemotherapy cycle may&#x000a0;have to be&#x000a0;decreased&#x000a0;or delayed, affecting patients' quality of life and worsening prognosis.</p>
      </sec>
      <sec id="article-19378.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Oral mucositis is a frequent complication in patients receiving radiation therapy (RT) to the head and neck, chemotherapy for solid tumors or lymphoma, and&#x000a0;high-dose myeloablative chemotherapy prior to hematopoietic cell transplantation. The incidence of oral mucositis varies amongst the different&#x000a0;chemotherapy agents.<xref ref-type="bibr" rid="article-19378.r3">[3]</xref>&#x000a0;Chemotherapeutic agents that affect DNA synthesis (S-phase), e.g., 5-fluorouracil, methotrexate, and cytarabine, have a high incidence of oral mucositis.<xref ref-type="bibr" rid="article-19378.r5">[5]</xref>&#x000a0;Anthracyclines, mTOR inhibitors, alkylating agents, and antimetabolites also&#x000a0;have an increased risk of oral mucositis.<xref ref-type="bibr" rid="article-19378.r6">[6]</xref><xref ref-type="bibr" rid="article-19378.r7">[7]</xref></p>
        <p>The basal epithelial layer&#x000a0;of the oral mucosa has a rapid cellular turnover, making the oral epithelium susceptible to radiation injury.<xref ref-type="bibr" rid="article-19378.r1">[1]</xref> Cell death and the incapacity of the oral mucosa to heal lead to the development of oral mucositis.<xref ref-type="bibr" rid="article-19378.r1">[1]</xref></p>
      </sec>
      <sec id="article-19378.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Between 20% to 40% of patients with solid tumors receiving chemotherapy develop mucositis, usually within five to&#x000a0;fourteen&#x000a0;days of starting treatment.<xref ref-type="bibr" rid="article-19378.r8">[8]</xref> The incidence and severity of mucositis vary between chemotherapeutic agents, the number of chemotherapy cycles, the dose of chemotherapy,&#x000a0;and from patient to patient.<xref ref-type="bibr" rid="article-19378.r5">[5]</xref>&#x000a0;Patients who receive myeloablative preparations for hematopoeitic stem cell transplant&#x000a0;have a higher incidence of oral mucositis.<xref ref-type="bibr" rid="article-19378.r9">[9]</xref></p>
        <p>One study reported that patients who receive high doses of chemotherapy or undergo bone marrow transplantation have a 76% risk of mucositis. Radiation-induced oral mucositis (RIOM) occurs in 100% of altered fractionation radiotherapy head and neck cancer patients.<xref ref-type="bibr" rid="article-19378.r10">[10]</xref>&#x000a0;The frequency of mucositis is higher in patients with poor nutritional status and&#x000a0;inadequate oral care. Younger age patients may have a higher incidence of oral mucositis.<xref ref-type="bibr" rid="article-19378.r9">[9]</xref></p>
      </sec>
      <sec id="article-19378.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology&#x000a0;of&#x000a0;oral mucositis due to radiation therapy, chemotherapy, or radiotherapy-chemotherapy is thought to be due to a complex process that starts with injury to the tissue in a five-phase model, as suggested by Sonis.<xref ref-type="bibr" rid="article-19378.r11">[11]</xref></p>
        <p>The five stages of OM induced by RT and chemotherapy occur consecutively, including initiation, signaling, amplification, ulceration, and healing. Firstly, tissue injury is caused by radiotherapy or chemotherapy, resulting in the death of the basal epithelial cells and the formation of reactive oxygen species.<xref ref-type="bibr" rid="article-19378.r3">[3]</xref>&#x000a0;Then, the reactive oxygen species cause direct cellular death and upregulate the inflammatory pathway to cause further cellular death.<xref ref-type="bibr" rid="article-19378.r3">[3]</xref>&#x000a0;Thirdly, other pathways are amplified, such as TNF alpha. Fourthly, mucosal ulcerations occur along with further inflammation. Lastly, the epithelium undergoes healing via epithelial proliferation.</p>
      </sec>
      <sec id="article-19378.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Radiotherapy-induced oral mucositis results from tissue damage by the radiation beam, usually appearing in the third week of treatment <xref ref-type="bibr" rid="article-19378.r8">[8]</xref> and lasting between 7 and 98 days.<xref ref-type="bibr" rid="article-19378.r10">[10]</xref>&#x000a0;The mucositis starts as acute inflammation in the oral mucosa, tongue, and pharynx.<xref ref-type="bibr" rid="article-19378.r10">[10]</xref>&#x000a0;The soft palate is most seriously damaged, followed by the hypopharynx, mouth floor, cheeks, tongue, and lips.<xref ref-type="bibr" rid="article-19378.r1">[1]</xref> Radiation-induced mucositis pain is usually severe, and, in many cases, the radiation treatment must be interrupted.<xref ref-type="bibr" rid="article-19378.r8">[8]</xref> Patients also complain of eating or speaking difficulty and may have increased bleeding while brushing.</p>
        <p>Oral mucositis due to chemotherapy usually develops within five to fourteen days of treatment.<xref ref-type="bibr" rid="article-19378.r8">[8]</xref> It starts as erythema in the mucosa, which subsequently becomes eroded and ulcerated. A white fibrinous pseudomembrane may cover the ulcerations. The location of ulcers is usually limited to non-keratinized surfaces of the mouth (buccal mucosa, lateral tongue, ventral tongue, and soft palate).<xref ref-type="bibr" rid="article-19378.r12">[12]</xref></p>
        <p>The oral mucositis starts to resolve as the absolute neutrophil count recovers in immunosuppressed patients or patients undergoing hematopoietic stem cell transplants.</p>
      </sec>
      <sec id="article-19378.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluating for oral mucositis is dependent upon clinical history and physical exam findings. Laboratory and radiography are not as helpful. If ulcers are present on the hard palate, attached gingiva, or tongue dorsum, cultures should be obtained to rule out viral or fungal etiology.</p>
        <p>The severity of mucositis is measured on a well-defined scale, and&#x000a0;several different scales have been developed.<xref ref-type="bibr" rid="article-19378.r4">[4]</xref></p>
        <p>
<bold>Common Terminology Criteria for Adverse Events (CTCAE)</bold>
</p>
        <p>The CTAE was developed by the National Cancer Institute (NCI) and is rated from 1 to 5. This scale is divided into two parts: a clinical exam and a functional/symptoms-based exam.&#x000a0;</p>
        <p>
<bold>Functional/Symptoms-Based Exam</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 1 = Asymptomatic or mild symptoms, and intervention is not indicated as well as the patient&#x000a0;maintains a normal diet.</p>
          </list-item>
          <list-item>
            <p>Grade 2 = Moderate pain or ulcer that does not interfere with oral intake, and the patient requires a modified diet.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Grade 3 = Severe pain which interferes with oral intake</p>
          </list-item>
          <list-item>
            <p>Grade 4 = Life-Threatening consequences that require urgent intervention</p>
          </list-item>
          <list-item>
            <p>Grade 5 = Death</p>
          </list-item>
        </list>
        <p>
<bold>Clinical Exam</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 1 = mucosal erythema</p>
          </list-item>
          <list-item>
            <p>Grade 2 = patchy ulceration or pseudomembranes</p>
          </list-item>
          <list-item>
            <p>Grade 3 = Minor trauma resulting in bleeding, confluent ulcers, or pseudomembranes.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Grade 4 = Tissue necrosis, spontaneous bleeding, life-threatening events.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Grade 5 = Death.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>World Health Organization (WHO)&#x000a0;</bold>
</p>
        <p>The World Health Organization (WHO) scale combines both subjective and objective measures of oral mucositis.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 0 = No oral mucositis</p>
          </list-item>
          <list-item>
            <p>Grade 1 = Erythema and soreness</p>
          </list-item>
          <list-item>
            <p>Grade 2 = Ulcers, able to eat solids</p>
          </list-item>
          <list-item>
            <p>Grade 3 = Ulcers, requires a liquid diet (due to mucositis)</p>
          </list-item>
          <list-item>
            <p>Grade 4 = Ulcers, alimentation not possible (due to mucositis)</p>
          </list-item>
        </list>
        <p>
<bold>Oral Mucositis Assessment Scale (OMAS)</bold>
</p>
        <p>The Oral Mucositis Assessment Scale (OMAS) is an objective scale that measures erythema and ulceration at nine sites within the oral cavity.<xref ref-type="bibr" rid="article-19378.r13">[13]</xref>&#x000a0;A&#x000a0;multi-center trial showed that this scale has high interobserver reproducibility and a strong correlation between the OMAS score and patient symptoms.<xref ref-type="bibr" rid="article-19378.r13">[13]</xref>&#x000a0;According to Sonis et al., using concomitant symptomatic measurements appeared to be unnecessary while using OMAS.<xref ref-type="bibr" rid="article-19378.r13">[13]</xref></p>
        <p><bold>Eastern Cooperative Oncology Group (ECOG) common toxicity </bold>criteria are used in oncology trials.</p>
      </sec>
      <sec id="article-19378.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Clinicians employ various options to manage oral mucositis in the setting of cancer therapy.<xref ref-type="bibr" rid="article-19378.r14">[14]</xref>&#x000a0;A brief description is provided here of the different&#x000a0;recommended treatment strategies.</p>
        <p>
<bold>Basic Oral Care</bold>
</p>
        <p>Basic oral care (BOC) is suggested by the 2020 Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) clinical guidelines for managing oral mucositis secondary to cancer therapy.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref>&#x000a0;BOC refers to all the interventions done by patients and clinicians to&#x000a0;prevent oral infections and alleviate patient discomfort, including&#x000a0;mechanical cleaning of teeth, mouth rinses, and lubricating the oral mucosa.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref>&#x000a0;Furthermore, frequent assessment of the oral tissues before and during cancer treatment reduces infection risk and helps identify the initial stages of oral mucositis.<xref ref-type="bibr" rid="article-19378.r15">[15]</xref></p>
        <p>Oral hygiene protocols prevent oral mucositis and decrease its duration and severity once it occurs by&#x000a0;reducing the microbial burden, hence, avoiding&#x000a0;secondary infections.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref><xref ref-type="bibr" rid="article-19378.r16">[16]</xref>&#x000a0;</p>
        <p>Prophylactic dental interventions, such as extracting compromised teeth and restoring carious lesions before initiating cancer therapy, can decrease mucositis risk by &#x0003e;25% and are particularly beneficial in high-risk patients.<xref ref-type="bibr" rid="article-19378.r8">[8]</xref></p>
        <p>
<bold>Mechanical Cleaning</bold>
</p>
        <p>Patients should be encouraged to enhance their regular mechanical cleaning practices, including increasing the frequency of tooth brushing, using a soft toothbrush, replacing the toothbrush regularly, and cleaning interproximally.<xref ref-type="bibr" rid="article-19378.r1">[1]</xref></p>
        <p>
<bold>Oral Rinses</bold>
</p>
        <p>Rinsing the oral cavity with&#x000a0;non-medicated oral rinses -&#x000a0;saline water rinse, sodium bicarbonate rinse, or a combination of sodium bicarbonate and saline water- is recommended every four hours.<xref ref-type="bibr" rid="article-19378.r1">[1]</xref> The MASCC/ISOO clinical guidelines state that despite the limited data on both saline and sodium bicarbonate oral rinses, the panel has recognized that these are inert and bland rinses that increase oral clearance, helps maintain oral hygiene and improve patient comfort.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref>&#x000a0;</p>
        <p>Chlorhexidine is not recommended to prevent radiotherapy-induced oral mucositis as no available data supports its benefit.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref><xref ref-type="bibr" rid="article-19378.r1">[1]</xref><xref ref-type="bibr" rid="article-19378.r2">[2]</xref></p>
        <p>
<bold>Antiinflamatory Agents</bold>
</p>
        <p>The MASCC/ISOO guidelines recommend benzydamine mouthwash for preventing oral mucositis in head and neck cancer patients receiving less than 50 Gy radiation dose (moderate dose) and in those receiving radiotherapy-chemotherapy (RT-CT).<xref ref-type="bibr" rid="article-19378.r2">[2]</xref></p>
        <p>
<bold>Hydration And Lubrication Of The Oral Mucosa</bold>
</p>
        <p>Patients should be advised to maintain adequate hydration and avoid irritants like tobacco and alcohol (as a beverage and alcohol-containing mouth rinses).<xref ref-type="bibr" rid="article-19378.r1">[1]</xref><xref ref-type="bibr" rid="article-19378.r8">[8]</xref><xref ref-type="bibr" rid="article-19378.r1">[1]</xref> Mousses and topical barrier gels can be used to lubricate the oral mucosa surfaces.<xref ref-type="bibr" rid="article-19378.r1">[1]</xref></p>
        <p>
<bold>Diet</bold>
</p>
        <p>The diet should be limited to food that does not aggravate the mucosa or risk injury during chewing. Food that may induce unintended trauma to the oral mucosa, such as spicy, sharp, and hard food, should be avoided.<xref ref-type="bibr" rid="article-19378.r8">[8]</xref></p>
        <p>
<bold>Pain Management</bold>
</p>
        <p>Topical morphine 0.2% mouth rinse is recommended by the MASCC/ISOO guidelines for managing pain in head and neck cancer patients receiving radiotherapy and chemotherapy.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref></p>
        <p>Other oral rinses have been formulated to manage pain, including the so-called &#x0201c;magic mouthwash.&#x0201d; This oral rinse usually contains an anesthetic, antacid, and diphenhydramine and may have steroids and anti-micotics.<xref ref-type="bibr" rid="article-19378.r15">[15]</xref>&#x000a0;However, a study of 26 patients receiving a dual treatment of RT and CT concluded that patients using topical morphine 0.2% mouth rinses had a shorter duration of severe pain and needed&#x000a0;less systemic analgesic treatment than those using the magic mouth rinse containing lidocaine, diphenhydramine, and magnesium aluminum hydroxide.<xref ref-type="bibr" rid="article-19378.r15">[15]</xref></p>
        <p>
<bold>Low-Level Laser Therapy</bold>
</p>
        <p>The local use of low-level light and laser therapy to induce a biological response is known as photobiomodulation (PBM).<xref ref-type="bibr" rid="article-19378.r2">[2]</xref>&#x000a0;PBM promotes the regeneration of affected tissue and prevents inflammation in animal models.<xref ref-type="bibr" rid="article-19378.r15">[15]</xref> Furthermore, clinical studies showed that low-level laser therapy (LLLT) reduces mucositis severity in patients receiving chemo-radiotherapy before hematopoietic stem cell transplantation.<xref ref-type="bibr" rid="article-19378.r15">[15]</xref></p>
        <p>The MASCC/ISOO guidelines recommend intraoral low-level laser therapy for the prevention of oral mucositis in the following clinical settings:</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult patients undergoing hematopoietic stem cell transplantation conditioned with high-dose chemotherapy, with or without total body irradiation.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Adult patients undergoing radiation therapy to the head and neck without chemotherapy - clinicians must take into account the safety considerations relevant to patients with oral cancer.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Adult patients undergoing radiotherapy-chemotherapy for head and neck cancer - clinicians must take into account the safety considerations relevant to patients with oral cancer.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>It is worth noting that although clinical evidence supports the use of LLLT in head and neck cancer patients, in vitro studies showed that LLLT can induce pro-tumorigenic signaling pathways in cancerous cells.<xref ref-type="bibr" rid="article-19378.r15">[15]</xref> Low-level laser therapy should not be applied to cancerous tissue, and patients must&#x000a0;be&#x000a0;closely followed.<xref ref-type="bibr" rid="article-19378.r15">[15]</xref></p>
        <p>
<bold>Cryotherapy</bold>
</p>
        <p>Cryotherapy refers to placing a source of cold in the oral cavity, usually ice or cold water, during the delivery of a cytotoxic agent (chemotherapy).<xref ref-type="bibr" rid="article-19378.r17">[17]</xref> Cooling the oral mucosa induces vasoconstriction, preventing the influx of cytotoxic drugs in the oral tissues and preventing oral mucositis.<xref ref-type="bibr" rid="article-19378.r17">[17]</xref> Low temperatures may also decrease the metabolism of the basal epithelial layer &#x02013; making the epithelium less prone to the damage caused by cytotoxic drugs.<xref ref-type="bibr" rid="article-19378.r18">[18]</xref></p>
        <p>The cooling of the oral mucosa is only temporary; therefore, this measure is indicated in conjunction with short chemotherapy protocols or when short half-life cytotoxic agents are used.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref>&#x000a0;The MASCC/ISOO guidelines recommend 30 minutes of oral cryotherapy during the administration of bolus 5-fluorouracil.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref>&#x000a0;Oral cryotherapy is also recommended for patients conditioned with high-dose melphalan undergoing autologous hematopoeitic stem cell transplantation.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref></p>
        <p>
<bold>Chemoprotective Agent</bold>
</p>
        <p>Palifermin is a keratinocyte growth factor and works as a chemoprotective agent, recommended for severe oral mucositis (mucositis greater than or equal to grade 3) associated with autologous hematopoietic stem cell transplant regimens.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref>&#x000a0;Palifermin decreases the incidence and duration of severe oral mucositis in such patients.</p>
        <p>
<bold>Zinc Supplementation</bold>
</p>
        <p>Zinc enhances tissue repair and provides antioxidant effects. The 2014 MASCC/ISOO guidelines recommended systemic zinc supplements to prevent OM in oral cancer patients undergoing radiotherapy or chemoradiation.<xref ref-type="bibr" rid="article-19378.r19">[19]</xref>&#x000a0;However, in the 2020 update of the guidelines, the panel reversed this recommendation to no guidelines possible.<xref ref-type="bibr" rid="article-19378.r2">[2]</xref></p>
      </sec>
      <sec id="article-19378.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses include the infectious process or dermatologic manifestation of another disease. Although infectious processes do not cause oral mucositis, the local infection can complicate the presentation of oral mucositis and require&#x000a0;adjuvant treatment. Viral infections such as herpes simplex virus and fungal infections such as candidiasis can be superimposed. Dermatologic manifestations of systemic inflammatory diseases&#x000a0;like systemic lupus erythematosus and rheumatoid arthritis can also cause oral ulcers. Oral squamous cell carcinoma may also present similarly. Nutritional deficiencies such as zinc deficiency can cause oral lesions, for which nutritionists often prescribe zinc supplementation.<xref ref-type="bibr" rid="article-19378.r20">[20]</xref></p>
      </sec>
      <sec id="article-19378.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Symptomatic treatment and palliative care may be sufficient to treat uncomplicated cases of mucositis, which are usually self-limiting.<xref ref-type="bibr" rid="article-19378.r8">[8]</xref>&#x000a0;However, nearly 20% of&#x000a0;head and neck cancer patients treated with chemo-radiotherapy require hospitalization and a delay in cancer therapy due to high-grade mucositis.<xref ref-type="bibr" rid="article-19378.r15">[15]</xref> This will disrupt patients' quality of life, worsen prognosis, and increase the use of health care resources.</p>
      </sec>
      <sec id="article-19378.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Oral mucositis results in severe pain and the&#x000a0;subsequent decrease in oral intake can lead to a significant deterioration in patient quality of life as well as nutritional status. This can also interrupt the chemotherapy treatment cycle, potentially worsening cancer outcomes. Mucositis also results in a breakdown of the protective mucosal barrier and thus increasing the susceptibility of the patient to infections. Therefore, chemotherapy protocols&#x000a0;that increase the risk of oral mucositis&#x000a0;have a prophylactic oral regimen and antibiotics built into them to prevent the development of oral mucositis and subsequent septicemia.<xref ref-type="bibr" rid="article-19378.r21">[21]</xref></p>
      </sec>
      <sec id="article-19378.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients must be informed regarding the signs and symptoms of oral mucositis before starting chemotherapy or radiotherapy carrying oral mucositis risk, as early diagnosis and intervention will improve outcomes. Patients should also be aware of alarming symptoms requiring emergency care like oral intake impairment or infection concern.<xref ref-type="bibr" rid="article-19378.r8">[8]</xref></p>
        <p>The importance of basic oral care measures, irritant avoidance, and appropriate diet should be emphasized, and a detailed explanation of these strategies is given above.</p>
      </sec>
      <sec id="article-19378.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Up to 91% of patients receiving radiotherapy for head and neck cancer and 20% to 40% of patients with solid tumors receiving chemotherapy&#x000a0;will develop mucositis.<xref ref-type="bibr" rid="article-19378.r8">[8]</xref>&#x000a0;Therefore, treating clinicians must&#x000a0;inform&#x000a0;patients regarding the signs and symptoms of oral mucositis before starting chemotherapy or radiotherapy so patients can identify early features and seek treatment. The treating clinician should also refer patients at risk of oral mucositis to a dentist for a complete oral examination before starting cancer treatment. Prophylactic dental interventions, such as extracting compromised teeth and restoring carious lesions before initiating cancer therapy, can decrease mucositis risk by &#x0003e;25% and are particularly beneficial in high-risk patients.<xref ref-type="bibr" rid="article-19378.r8">[8]</xref>&#x000a0;</p>
        <p>The importance of basic oral care measures, irritant avoidance, and appropriate diet should be emphasized by all interprofessional healthcare team members, including clinicians (MDs, DOs, NPs, and PAs), dentists, and nurses. An interprofessional group of specialists should be in charge of managing oral mucositis cases to improve patients' outcomes.</p>
      </sec>
      <sec id="article-19378.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19378&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19378">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/oral-health/oral-mucositis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19378">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19378/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19378">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19378.s15">
        <title>References</title>
        <ref id="article-19378.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beech</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Porceddu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Batstone</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dental management of patients irradiated for head and neck cancer.</article-title>
            <source>Aust Dent J</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-8</page-range>
            <pub-id pub-id-type="pmid">24495127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>KKF</given-names>
              </name>
              <name>
                <surname>Lalla</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Yarom</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Logan</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bowen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Zadik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ariyawardana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ranna</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bossi</surname>
                <given-names>P</given-names>
              </name>
              <collab>Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO)</collab>
            </person-group>
            <article-title>MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.</article-title>
            <source>Cancer</source>
            <year>2020</year>
            <month>Oct</month>
            <day>01</day>
            <volume>126</volume>
            <issue>19</issue>
            <fpage>4423</fpage>
            <page-range>4423-4431</page-range>
            <pub-id pub-id-type="pmid">32786044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sonis</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Elting</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Keefe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Schubert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hauer-Jensen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bekele</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Raber-Durlacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Rubenstein</surname>
                <given-names>EB</given-names>
              </name>
              <collab>Mucositis Study Section of the Multinational Association for Supportive Care in Cancer</collab>
              <collab>International Society for Oral Oncology</collab>
            </person-group>
            <article-title>Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients.</article-title>
            <source>Cancer</source>
            <year>2004</year>
            <month>May</month>
            <day>01</day>
            <volume>100</volume>
            <issue>9 Suppl</issue>
            <fpage>1995</fpage>
            <page-range>1995-2025</page-range>
            <pub-id pub-id-type="pmid">15108222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lalla</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Sonis</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Management of oral mucositis in patients who have cancer.</article-title>
            <source>Dent Clin North Am</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-77, viii</page-range>
            <pub-id pub-id-type="pmid">18154865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naidu</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Ramana</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Rani</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Suman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy-induced and/or radiation therapy-induced oral mucositis--complicating the treatment of cancer.</article-title>
            <source>Neoplasia</source>
            <year>2004</year>
            <season>Sep-Oct</season>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>423</fpage>
            <page-range>423-31</page-range>
            <pub-id pub-id-type="pmid">15548350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valer</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Curra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>MBC</given-names>
              </name>
              <name>
                <surname>Roesler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Evangelista</surname>
                <given-names>JMC</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>MAT</given-names>
              </name>
              <name>
                <surname>Gregianin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Oral mucositis in childhood cancer patients receiving high-dose methotrexate: Prevalence, relationship with other toxicities and methotrexate elimination.</article-title>
            <source>Int J Paediatr Dent</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>238</fpage>
            <page-range>238-246</page-range>
            <pub-id pub-id-type="pmid">32815183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barasch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions.</article-title>
            <source>Oral Oncol</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-100</page-range>
            <pub-id pub-id-type="pmid">12509961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of Cancer Therapy-Associated Oral Mucositis.</article-title>
            <source>JCO Oncol Pract</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>103</fpage>
            <page-range>103-109</page-range>
            <pub-id pub-id-type="pmid">32048926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vagliano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Feraut</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gobetto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Trunfio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Errico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Costazza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mega</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matozzo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Berni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alberani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Banfi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Munaron</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Orlando</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lubiato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leanza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guerrato</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barzetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Satta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dimonte</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT--results of a multicentre study.</article-title>
            <source>Bone Marrow Transplant</source>
            <year>2011</year>
            <month>May</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>727</fpage>
            <page-range>727-32</page-range>
            <pub-id pub-id-type="pmid">20818449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maria</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Eliopoulos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Muanza</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Radiation-Induced Oral Mucositis.</article-title>
            <source>Front Oncol</source>
            <year>2017</year>
            <volume>7</volume>
            <fpage>89</fpage>
            <pub-id pub-id-type="pmid">28589080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sonis</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Pathobiology of oral mucositis: novel insights and opportunities.</article-title>
            <source>J Support Oncol</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>9 Suppl 4</issue>
            <fpage>3</fpage>
            <page-range>3-11</page-range>
            <pub-id pub-id-type="pmid">18046993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lalla</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Oral mucositis.</article-title>
            <source>Dent Clin North Am</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>167</fpage>
            <page-range>167-84, ix</page-range>
            <pub-id pub-id-type="pmid">15567367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sonis</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Eilers</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>LeVeque</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Liggett</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Mulagha</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Schubert</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Spijkervet</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Wittes</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group.</article-title>
            <source>Cancer</source>
            <year>1999</year>
            <month>May</month>
            <day>15</day>
            <volume>85</volume>
            <issue>10</issue>
            <fpage>2103</fpage>
            <page-range>2103-13</page-range>
            <pub-id pub-id-type="pmid">10326686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubenstein</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Schubert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keefe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elting</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Cooksley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sonis</surname>
                <given-names>ST</given-names>
              </name>
              <collab>Mucositis Study Section of the Multinational Association for Supportive Care in Cancer</collab>
              <collab>International Society for Oral Oncology</collab>
            </person-group>
            <article-title>Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis.</article-title>
            <source>Cancer</source>
            <year>2004</year>
            <month>May</month>
            <day>01</day>
            <volume>100</volume>
            <issue>9 Suppl</issue>
            <fpage>2026</fpage>
            <page-range>2026-46</page-range>
            <pub-id pub-id-type="pmid">15108223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pulito</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cristaudo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Porta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zapperi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blandino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morrone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strano</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Oral mucositis: the hidden side of cancer therapy.</article-title>
            <source>J Exp Clin Cancer Res</source>
            <year>2020</year>
            <month>Oct</month>
            <day>07</day>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>210</fpage>
            <pub-id pub-id-type="pmid">33028357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eilers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based interventions for cancer treatment-related mucositis: putting evidence into practice.</article-title>
            <source>Clin J Oncol Nurs</source>
            <year>2014</year>
            <volume>18 Suppl</volume>
            <fpage>80</fpage>
            <page-range>80-96</page-range>
            <pub-id pub-id-type="pmid">25427611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Correa</surname>
                <given-names>MEP</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>KKF</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kandwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loprinzi</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Potting</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rouleau</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Toro</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ranna</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vaddi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bossi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lalla</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Elad</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines.</article-title>
            <source>Support Care Cancer</source>
            <year>2020</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>2449</fpage>
            <page-range>2449-2456</page-range>
            <pub-id pub-id-type="pmid">31836937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walladbegi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Grayson</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Murdoch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jontell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Colley</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Cooling of the oral mucosa to prevent adverse effects of chemotherapeutic agents: An in&#x000a0;vitro study.</article-title>
            <source>J Oral Pathol Med</source>
            <year>2018</year>
            <month>May</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>477</fpage>
            <page-range>477-483</page-range>
            <pub-id pub-id-type="pmid">29469972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lalla</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Bowen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barasch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elting</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keefe</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Migliorati</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nicolatou-Galitis</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Raber-Durlacher</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Sonis</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Elad</surname>
                <given-names>S</given-names>
              </name>
              <collab>Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO)</collab>
            </person-group>
            <article-title>MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.</article-title>
            <source>Cancer</source>
            <year>2014</year>
            <month>May</month>
            <day>15</day>
            <volume>120</volume>
            <issue>10</issue>
            <fpage>1453</fpage>
            <page-range>1453-61</page-range>
            <pub-id pub-id-type="pmid">24615748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozler</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Zinc deficiency in patients with recurrent aphthous stomatitis: a pilot study.</article-title>
            <source>J Laryngol Otol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>128</volume>
            <issue>6</issue>
            <fpage>531</fpage>
            <page-range>531-3</page-range>
            <pub-id pub-id-type="pmid">24849699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19378.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Taie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Shohani</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Albasry</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Altaee</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Current topical trends and novel therapeutic approaches and delivery systems for oral mucositis management.</article-title>
            <source>J Pharm Bioallied Sci</source>
            <year>2020</year>
            <season>Apr-Jun</season>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>94</fpage>
            <page-range>94-101</page-range>
            <pub-id pub-id-type="pmid">32742107</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
